|
Dubai, United Arab Emirates -
Wednesday, January 23rd 2013 [ME NewsWire]
New
research programme unveiled by Boehringer Ingelheim and the European Foundation
for the Study of Diabetes (EFSD) invites European diabetes research projects to
apply for funding.
The Boehringer Ingelheim and EFSD
diabetes partnershiphas opened submissions for diabetes research grant
applications from across Europe. In a collaboration which aims to stimulate and
accelerate European research in diabetes, the EFSD/Boehringer Ingelheim European
Diabetes Research Programmes
have dedicated more than 2.5 million euros over three years to support research
projects targeting specific areas of interest.
"Diabetes affects more than
371 million people worldwide and diabetes remains undiagnosed in up to 50% of
cases,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine,
Boehringer Ingelheim."We are delighted to partner with the EFSD on this
initiative and hope the grant encourages and supports new research in the field
of diabetes.”
The joint diabetes grant programme
will focus on two areas of interest in order to achieve the goals and
objectives of the programmes and will welcome proposals which target the
following:
1. Regulations of secretion
and/or function of non-insulin peptides from the endocrine pancreas. (Basic
research)
2. Mechanisms relating renal
dysfunction to cardiovascular disease in type 2 diabetes. (Clinical Research)
The EFSD/Boehringer
Ingelheim European Diabetes Research Programmeswill consider funding of
basic research projects up to 100,000 euros in total for projects lasting up to
2 years, and clinical research projects up to 400,000 euros in total for
projects up to 3 years in duration. Funding applications for research
projects will be accepted until 1 April 2013.
"The EFSD is proud to collaborate
once again with Boehringer Ingelheim on this important research initiative,”
said Dr. Viktor Joergens, Executive Director and Vice Director, EFSD. "Ensuring
sufficient funding for diabetes research in Europe is vital and we hope that
this partnership leads the way to provide invaluable contributions to diabetes
research.”
Commenting on the Initiative, Mr.
Karim El Alaoui, Boehringer Ingelheim Managing Director for Middle East and
North Africa, said "the initiative supports Boehringer Ingelheim commitment
towards serving humankind through research. The MENA region has the
highest comparative prevalence of diabetes equates to 11.0%,1 so we are hoping
that we could implement the initiative in the Middle East region in the near
future to be able to add to the disease literature of the region”.
Applications are invited from single
non-profit institutions or groups of institutions in Europe and will be subject
to a scientific review by a specialised and independent committee. The ad
hoc committee will review the grant applications on criteria such as
significance, approach and innovation. Researchers who are interested in
applying for a grant can download an application form from
www.EuropeanDiabetesFoundation.org.
The deadline for submissions is 1
April 2013 and the anticipated award date is in June 2013.
###
About Diabetes
An estimated 371 million people
worldwide have Type 1 and Type 2 Diabetes.2 Type 2 Diabetes is the most common
type, accounting for an estimated 90% of all diabetes cases.3 Diabetes is a
chronic condition that occurs when the body either does not properly produce,
or use, the hormone insulin.4
About Boehringer Ingelheim
The Boehringer Ingelheim group is
one of the world’s 20 leading pharmaceutical companies. Headquartered in
Ingelheim, Germany, it operates globally with 145 affiliates and more than
44,000 employees. Since it was founded in 1885, the family-owned company has
been committed to researching, developing, manufacturing and marketing novel
medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture,
Boehringer Ingelheim pledges to act with social responsibility. Involvement in
social projects, caring for employees and their families, and providing equal
opportunities for all employees form the foundation of the global operations.
Mutual cooperation and respect, as well as environmental protection and
sustainability are intrinsic factors in all of Boehringer Ingelheim’s
endeavours.
In 2011, Boehringer Ingelheim
achieved net sales of about 13.2 billion euro. R&D expenditure in the
business area Prescription Medicines corresponds to 23.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
About the EFSD:
The European Foundation for the
Study of Diabetes (EFSD) was created by the European Association for the Study
of Diabetes (EASD) to provide multiple funding initiatives in all areas of
diabetes research. The aims of EFSD are to encourage and support research in
the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate
its application.
References:
1.
International Diabetes Federation. What is Diabetes?. IDF Diabetes Atlas.
2011(5th Edition).
2.
International Diabetes Federation. IDF Diabetes Atlas Poster. 2012 Update.
2012(5th Edition).
3.
World Health Organization: Fact Sheet No. 312 What is Diabetes?, 2010.
4.
International Diabetes Federation. What is Diabetes?. IDF Diabetes Atlas.
2011(5th Edition).
Contacts
Boehringer
Ingelheim
PR
Manager
Omneya
Fawzy
+971 4
4230471
omneya.fawzy@boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/6775/en
| 
